Research programme: alpha-klotho protein targeting therapeutics - UNITY Biotechonology/University of California
Latest Information Update: 28 Sep 2021
At a glance
- Originator University of California at San Francisco
- Developer UNITY Biotechnology; University of California at San Francisco
- Class Nootropics
- Mechanism of Action Klotho protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cognition-disorders in USA (Parenteral)
- 01 Mar 2021 UNITY Biotechnology has patent protection for alpha-Klotho protein and variants in USA, Australia, Japan
- 01 Mar 2021 UNITY Biotechnology has patents pending for alpha-Klotho protein and variants in USA, Canada, Europe, Hong Kong, India and China